Market news

GoodRx, a prescription drug savings site, announced a family healthcare subscription for access to common medical services and over 250 medications.

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at GoodRx (NASDAQ:GDRX) and its peers.

GoodRx Holdings has delivered a steep 89.7% share price decline over the past five years. The stock has recently bounced, which sits awkwardly with valuation checks that currently lean toward the shares looking expensive rather than clearly mispriced on the downside. The stock is down 89.7% over five years, which suggests long term holders have worn a heavy loss despite the recent short term recovery. Future progress on converting its platform usage into consistent cash generation can...

GoodRx Holdings (GDRX) is back in focus after its Q2 2026 earnings report on 5 August, along with raised full-year revenue guidance and a leadership change that appoints Justin Fengler as Chief Financial Officer. See our latest analysis for GoodRx Holdings. The Q2 earnings update and CFO transition come after a period of sharp share price moves for GoodRx Holdings. The stock has a 90 day share price return of 44.18% and a year to date share price return of 30.55%. However, the 3 year total...

Pharma Direct revenue surged 76% as GLP-1 demand accelerated.

GoodRx rebounds from $2.50 with improved traction and new offerings, but valuation and risk stay balanced. Click here to read an analysis of GDRX stock now.

Moby summary of GoodRx Holdings, Inc.'s Q2 2026 earnings call

GoodRx (GDRX) delivered earnings and revenue surprises of 0.00% and +3.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 1.3% year on year to $200.4 million. The company’s full-year revenue guidance of $797.5 million at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $0.08 per share was in line with analysts’ consensus estimates.

SANTA MONICA, Calif., August 05, 2026--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2026.

GoodRx has had an impressive run over the past six months as its shares have beaten the S&P 500 by 13.1%. The stock now trades at $3.14, marking a 21.5% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Check out the companies making headlines yesterday:

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 2.6% in the afternoon session after the company announced a partnership with Paytient, a healthcare affordability solutions provider.

GoodRx Holdings stock has seen a steep share price decline over the past few years, yet on current checks it still screens as relatively expensive on market multiples and only a mixed value story overall. Over the past 5 years, GoodRx Holdings has delivered a share price decline of about 90%, which sets a cautious backdrop for any case that the current valuation now looks attractive. Future growth in prescription transaction volume and adherence to its discount platform can support earnings...

GoodRx Holdings (GDRX) continues to attract attention as investors weigh its recent share price moves, with the stock closing at $2.95 and recent returns over the month and past 3 months diverging from its longer term record. See our latest analysis for GoodRx Holdings. That recent 30 day share price return of 11.32% and 90 day share price return of 37.21% contrasts with a 1 year total shareholder return that declined 37.83%. This suggests short term momentum is improving while longer term...

SANTA MONICA, Calif., July 09, 2026--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 5, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 6, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s busine

GDRX vs. HQY: Which Stock Is the Better Value Option?

GoodRx (GDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).